Mon Sep 23 21:31:00 UTC 2024: ## New Therapies Surge in Non-Muscle Invasive Bladder Cancer (NMIBC) Market

**LAS VEGAS, Sept. 23, 2024** – The market for non-muscle invasive bladder cancer (NMIBC) is rapidly expanding, with a projected influx of 13 new therapies by 2034. According to market research firm DelveInsight, this growth is driven by the increasing prevalence of NMIBC, the high cost of current treatments, and the need for new treatment options.

DelveInsight predicts that three of these new therapies will generate billion-dollar markets by 2034, highlighting the significant potential within this space.

**Current Treatment Landscape:**

Currently, NMIBC is primarily treated with surgery, intravesical immunotherapy (BCG), and intravesical chemotherapy. However, the traditional treatment, BCG, has faced shortages, forcing doctors to explore alternative options.

**New Therapies: A Wave of Innovation:**

The FDA has approved three drugs for NMIBC: KEYTRUDA, ADSTILADRIN, and ANKTIVA, all of which are only available in the United States. Several promising therapies are also in development, including:

* **CG0070 (CG Oncology):** An oncolytic immunotherapy currently in Phase III trials, showcasing potential for BCG-unresponsive NMIBC.
* **TAR-002 (Johnson & Johnson):** A new treatment option targeting intermediate-risk NMIBC.
* **Ruvidar (Theralase Technologies):** A promising therapy undergoing clinical evaluation.
* **ONCOFID P-B (Fidia Farmaceutici):** A chemotherapy-based option in Phase III trials.
* **EG-70 (enGene):** A non-viral plasmid-based therapy expected to compete with existing viral therapies.

**Focus on BCG-Naive Patients and Intermediate Risk NMIBC:**

The market for BCG-naive patients and intermediate-risk NMIBC represents a significant growth opportunity. Many companies are developing treatments for these segments, particularly Urogen, CG Oncology, Johnson & Johnson, and Ferring Pharmaceuticals.

**Future Outlook:**

The influx of new therapies is set to transform the NMIBC market, offering new treatment options and driving innovation. DelveInsight projects the total market size for NMIBC to reach USD 2.6 billion by 2034, with a significant CAGR of 15%.

**For more insights into the NMIBC market, consult DelveInsight’s latest report, “Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insight, Epidemiology And Market Forecast – 2034.”**

**About DelveInsight:**

DelveInsight is a leading business consultant and market research firm focused on life sciences. They provide comprehensive end-to-end solutions to help pharma companies improve their performance.

Read More